High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis

被引:1
作者
Bejko, Dritan [1 ,6 ]
Ernst, Corinna [1 ]
Vergison, Anne [1 ]
Stranges, Saverio [2 ,3 ,4 ,5 ]
Zeegers, Maurice P. [6 ]
Mossong, Joel [1 ]
机构
[1] Hlth Directorate, Hlth Inspectorate, Luxembourg, Luxembourg
[2] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Dept Family Med, London, ON, Canada
[4] Western Univ, Dept Med, London, ON, Canada
[5] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Epidemiol, Maastricht, Netherlands
关键词
Vaccine effectiveness; Natural immunity; COVID-19; Retrospective cohort; Hospital admission; Mortality;
D O I
10.1016/j.vaccine.2024.05.059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. Methods: We linked reported SARS-CoV-2 cases among residents aged >= 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. Results: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1 728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). Conclusions: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
收藏
页数:9
相关论文
共 27 条
  • [1] Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
    Amirthalingam, Gayatri
    Bernal, Jamie Lopez
    Andrews, Nick J.
    Whitaker, Heather
    Gower, Charlotte
    Stowe, Julia
    Tessier, Elise
    Subbarao, Sathyavani
    Ireland, Georgina
    Baawuah, Frances
    Linley, Ezra
    Warrener, Lenesha
    O'Brien, Michelle
    Whillock, Corinne
    Moss, Paul
    Ladhani, Shamez N.
    Brown, Kevin E.
    Ramsay, Mary E.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [2] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [3] [Anonymous], 2020, Loi du 17 juillet 2020 sur les mesures de lutte contre la pandemie Covid-19
  • [4] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
    Baden, Lindsey R.
    El Sahly, Hana M.
    Essink, Brandon
    Kotloff, Karen
    Frey, Sharon
    Novak, Rick
    Diemert, David
    Spector, Stephen A.
    Rouphael, Nadine
    Creech, C. Buddy
    McGettigan, John
    Khetan, Shishir
    Segall, Nathan
    Solis, Joel
    Brosz, Adam
    Fierro, Carlos
    Schwartz, Howard
    Neuzil, Kathleen
    Corey, Larry
    Gilbert, Peter
    Janes, Holly
    Follmann, Dean
    Marovich, Mary
    Mascola, John
    Polakowski, Laura
    Ledgerwood, Julie
    Graham, Barney S.
    Bennett, Hamilton
    Pajon, Rolando
    Knightly, Conor
    Leav, Brett
    Deng, Weiping
    Zhou, Honghong
    Han, Shu
    Ivarsson, Melanie
    Miller, Jacqueline
    Zaks, Tal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) : 403 - 416
  • [5] SARS-CoV-2 Reinfections and Long COVID in the Post-Omicron Phase of the Pandemic
    Boufidou, Fotini
    Medic, Snezana
    Lampropoulou, Vicky
    Siafakas, Nikolaos
    Tsakris, Athanasios
    Anastassopoulou, Cleo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [6] Global disparities in SARS-CoV-2 genomic surveillance
    Brito, Anderson F.
    Semenova, Elizaveta
    Dudas, Gytis
    Hassler, Gabriel W.
    Kalinich, Chaney C.
    Kraemer, Moritz U. G.
    Ho, Joses
    Tegally, Houriiyah
    Githinji, George
    Agoti, Charles N.
    Matkin, Lucy E.
    Whittaker, Charles
    Howden, Benjamin P.
    Sintchenko, Vitali
    Zuckerman, Neta S.
    Mor, Orna
    Blankenship, Heather M.
    de Oliveira, Tulio
    Lin, Raymond T. P.
    Siqueira, Marilda Mendonca
    Resende, Paola Cristina
    Vasconcelos, Ana Tereza R.
    Spilki, Fernando R.
    Aguiar, Renato Santana
    Alexiev, Ivailo
    Ivanov, Ivan N.
    Philipova, Ivva
    Carrington, Christine V. F.
    Sahadeo, Nikita S. D.
    Gurry, Celine
    Maurer-Stroh, Sebastian
    Naidoo, Dhamari
    von Eije, Karin J.
    Perkins, Mark D.
    van Kerkhove, Maria
    Hill, Sarah C.
    Sabino, Ester C.
    Pybus, Oliver G.
    Dye, Christopher
    Bhatt, Samir
    Flaxman, Seth
    Suchard, Marc A.
    Grubaugh, Nathan D.
    Baele, Guy
    Faria, Nuno R.
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] No country is safe from a pandemic: insights into small countries' COVID-19 experiences
    Cuschieri, Sarah
    Bejko, Dritan
    Stranges, Saverio
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33 (06) : 957 - 958
  • [8] European Centre for Disease Prevention and Control, Data on COVID-19 vaccination in the EU/EEA
  • [9] Sex and Gender Differences in the Outcomes of Vaccination over the Life Course
    Flanagan, Katie L.
    Fink, Ashley L.
    Plebanski, Magdalena
    Klein, Sabra L.
    [J]. ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 33, 2017, 33 : 577 - 599
  • [10] Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
    Gram, Mie Agermose
    Emborg, Hanne-Dorthe
    Schelde, Astrid Blicher
    Friis, Nikolaj Ulrik
    Nielsen, Katrine Finderup
    Moustsen-Helms, Ida Rask
    Legarth, Rebecca
    Lam, Janni Uyen Hoa
    Chaine, Manon
    Malik, Aisha Zahoor
    Rasmussen, Morten
    Fonager, Jannik
    Sieber, Raphael Niklaus
    Stegger, Marc
    Ethelberg, Steen
    Valentiner-Branth, Palle
    Hansen, Christian Holm
    [J]. PLOS MEDICINE, 2022, 19 (09)